Companies/US/RGEN

REPLIGEN CORPORATION

Last · NasdaqGS$184.17+5.97 (+3.35%)live · yahoo · 1h ago
Vol 1.04M ≈ 192.04M
Market cap$11.69B63.5M sh
P/E · TTM249fwd 69.0 · eps 0.74
Beta—vs S&P 500
Div yield0.00%annual · TTM
52w range
$100.99$198.87
Volume1.0Msession

Issuer

Legal nameREPLIGEN CORPORATION
HQUnited States (US)
ListingUS RGEN
ISINUS7599161095
LEI54930006QJ0T5AUO1E71
SectorHealthcare
IndustryMedical Equipment, Supplies & Distribution
SIC2836
CurrencyUSD
Entity registrysec:0000730272
CIK0000730272
Websitewww.repligen.com
LinkedIn
Employees2,000
AddressRepligen Corp. Building 1 02453, Waltham +781 250 0111
Headline financial metrics
Revenue$634.4M
Operating income$-35.1M
Net income$-25.5M
Free cash flow$149.7M
Operating margin-5.5%
Net margin-4.0%
Return on equity-1.3%
Period2024
Loading chart…

Upcoming earnings

1 event
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
$0.46
Est. revenue
206.7M
View upcoming earnings →

Press & signals

3 recent
  • GlobeNewswire

    Repligen Completes Acquisition of BioLife Solutions

  • GlobeNewswire

    Repligen Reports Second Quarter 2026 Financial Results and Updates Full Year 2026 Financial Guidance

  • GlobeNewswire

    Repligen to Acquire BioLife Solutions, Expanding Its Cell Therapy Capabilities with Market Leading Biopreservation Media

Documents

FormReporting forFiledFlags
proxy2026 Proxy StatementIR
—2026-12-31≈0
4
2026-10-062026-10-080
8-KCurrent Report (8-K)
—2026-10-060
4
2026-10-052026-10-060
4
2026-10-022026-10-050
Showing 5 of 133 filings